Lummus Technology

Photo
17.04.2023 • News

Lummus and RWDC Link on Polyhydroxyalkanoates

Lummus Technology and US biotech RWDC Industries have signed a Memorandum of Understanding to cooperate on deploying polyhydroxyalkanoates (PHAs), a group of natural biodegradable polyesters that are a sustainable alternative to fossil-based plastics.

Photo
15.02.2022 • News

Synthos and Lummus Make Progress on Bio-butadiene Technology

Synthos, Lummus Technology and the latter's Green Circle business are moving into the engineering and design phase of a project to commercialize bio-butadiene technology, following the successful completion of a feasibility study last year.

Photo
26.03.2021 • News

Lummus wins China EB Contract

Lummus Technology has won a contract for its proprietary EBOne ethylbenzene process from a firm in China’s Jiangsu province that will build a unit for 508,000 t/y of EB. A start-up date was not revealed. Lummus said the Chinese company has previously licensed its technologies, including the BP paraxylene process and Chevron Lummus Global’s Isocracking technology.

Photo
17.12.2020 • News

Lummus Wins Indonesia, China Contracts

Lummus Technology and its joint venture partner Chevon Lummus Global (CLG) have won multiple technology contracts from Pertamina Rosneft Pengolahan dan Petrokimia (PRPP), a joint venture between Indonesia’s Pertamina and Russia’s Rosneft Oil, for a grassroots refinery and petrochemical complex in Tuban, Indonesia.

Photo
15.10.2020 • News

Lummus Forms Green Circle Business

US process licensor Lummus Technology has established a new business called Green Circle that will expand its capabilities and capture new opportunities in the energy transition and circular economy.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.